株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

市場スポットライト:原発性硬化性胆管炎 (PSC)

Market Spotlight: Primary Sclerosing Cholangitis

発行 Datamonitor Healthcare 商品コード 603964
出版日 ページ情報 英文 28 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
市場スポットライト:原発性硬化性胆管炎 (PSC) Market Spotlight: Primary Sclerosing Cholangitis
出版日: 2019年10月07日 ページ情報: 英文 28 Pages
概要

当レポートでは、世界の原発性硬化性胆管炎 (PSC) 治療薬市場について調査分析し、疾患の背景、治療概要、主なパイプライン薬、治験、有病率10ヶ年予測など、体系的な情報を提供しています。

要点

疾患の背景

治療

疫学

パイプライン薬

これから起きる出来事

治験情勢

参考文献

付録

目次
Product Code: DMKC0185608

Primary sclerosing cholangitis (PSC) is a progressive, rare, and chronic cholestatic liver disorder that is characterized by thickening, inflammation, and fibrosis of the bile ducts. Both intra- and extra-hepatic bile ducts are affected. This generally leads to cholestasis, liver cirrhosis, and eventually liver failure.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were 232,900 prevalent cases of primary sclerosing cholangitis (PSC) worldwide among adults aged 30 years and over, and forecasts that number to increase to 270,300 prevalent cases by

2026. The majority of industry-sponsored drugs in active clinical development for PSC are in Phase II, with only two drugs in Phase III. Therapies in the pipeline for PSC focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route, with the remainder being tested in intravenous and subcutaneous formulations.

The only high-impact upcoming event for drugs in the PSC space is topline Phase II trial results for PLN-74809. The overall likelihood of approval of a Phase I autoimmune/immunology-other asset is 21.8%, and the average probability a drug advances from Phase III is 70.5%. Drugs, on average, take 10.1 years from Phase I to approval, compared to 9.0 years in the overall autoimmune/immunology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for PSC have been in the early and midphases of development, with 80% of trials in Phase I-II, and only 20% in Phase III.

The US leads in terms of the number of PSC clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.

In the PSC space, Gilead Sciences has two completed trials, and one ongoing trial.

Gilead Sciences has conducted two Phase II trials for PSC, and one Phase I and Phase III trial.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

EPIDEMIOLOGY

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Cilofexor for PSC (November 9, 2018)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • BiomX Acquires PSC Targets From Japanese University

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of PSC, 2017-26
  • Figure 2: Overview of pipeline drugs for PSC in the US
  • Figure 3: Pipeline drugs for PSC, by company
  • Figure 4: Pipeline drugs for PSC, by drug type
  • Figure 5: Pipeline drugs for PSC, by classification
  • Figure 6: Cilofexor for PSC (November 9, 2018): Phase II - Without Cirrhosis
  • Figure 7: Key upcoming events in PSC
  • Figure 8: Probability of success in the PSC pipeline
  • Figure 9: Clinical trials in PSC
  • Figure 10: Top 10 drugs for clinical trials in PSC
  • Figure 11: Top 10 companies for clinical trials in PSC
  • Figure 12: Trial locations in PSC
  • Figure 13: PSC trials status
  • Figure 14: PSC trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of PSC, 2017-26
  • Table 2: Pipeline drugs for PSC in the US
  • Table 3: Cilofexor for PSC (November 9, 2018
Back to Top